IL162269A0 - Methods and compositions for control of bone formation via modulation of sympathetic tone - Google Patents

Methods and compositions for control of bone formation via modulation of sympathetic tone

Info

Publication number
IL162269A0
IL162269A0 IL16226902A IL16226902A IL162269A0 IL 162269 A0 IL162269 A0 IL 162269A0 IL 16226902 A IL16226902 A IL 16226902A IL 16226902 A IL16226902 A IL 16226902A IL 162269 A0 IL162269 A0 IL 162269A0
Authority
IL
Israel
Prior art keywords
compositions
methods
control
bone formation
formation via
Prior art date
Application number
IL16226902A
Other languages
English (en)
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of IL162269A0 publication Critical patent/IL162269A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL16226902A 2001-12-05 2002-10-31 Methods and compositions for control of bone formation via modulation of sympathetic tone IL162269A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33705401P 2001-12-05 2001-12-05
PCT/US2002/034920 WO2003049673A2 (en) 2001-12-05 2002-10-31 Methods and compositions for control of bone formation via modulation of sympathetic tone

Publications (1)

Publication Number Publication Date
IL162269A0 true IL162269A0 (en) 2005-11-20

Family

ID=23318914

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16226902A IL162269A0 (en) 2001-12-05 2002-10-31 Methods and compositions for control of bone formation via modulation of sympathetic tone

Country Status (8)

Country Link
US (1) US20060165683A1 (de)
EP (2) EP1542719A4 (de)
JP (1) JP2005516001A (de)
CN (1) CN1630514A (de)
AU (1) AU2002348131A1 (de)
CA (1) CA2469306A1 (de)
IL (1) IL162269A0 (de)
WO (1) WO2003049673A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2566746A1 (en) * 2004-05-14 2005-12-01 Baylor College Of Medicine Beta adrenergic drug conjugated to bone targeting moiety for modulating bone mass
US8716220B2 (en) * 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
WO2009045900A2 (en) * 2007-09-28 2009-04-09 The Trustees Of Columbia University In The City Of New York Methods for treating or preventing diseases associated with low bone mass
AU2009231892A1 (en) * 2008-03-31 2009-10-08 The Trustees Of Columbia University In The City Of New York Methods of diagnosing, preventing and treating bone mass diseases
CA2725143A1 (en) * 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
WO2010056992A1 (en) 2008-11-13 2010-05-20 The Trustees Of Columbia University In The City Of New York Methods of preventing and treating low bone mass diseases
WO2010117785A1 (en) * 2009-03-31 2010-10-14 Temple University - Of The Commonwealth System Of Higher Education Leptin antagonist and methods of use
TW202417497A (zh) * 2015-10-12 2024-05-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4109496A (en) 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4710384A (en) 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
ATE117375T1 (de) 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
US5328899A (en) 1988-07-15 1994-07-12 The Salk Institute For Biological Studies NPY peptide analogs
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6274706B1 (en) 1989-01-25 2001-08-14 Centre National De La Recherche Scientifique Intron/exon of the human and mouse beta 3-adrenergic receptor genes
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5075217A (en) 1989-04-21 1991-12-24 Marshfield Clinic Length polymorphisms in (dC-dA)n ·(dG-dT)n sequences
US5053337A (en) 1989-10-30 1991-10-01 Neurogenetic Corporation DNA encoding an α2B -adrenergic receptor
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
CN1061623A (zh) 1990-06-01 1992-06-03 里珍纳龙药品有限公司 睫状神经营养性因子受体
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5364759B2 (en) 1991-01-31 1999-07-20 Baylor College Medicine Dna typing with short tandem repeat polymorphisms and identification of polymorphic short tandem repeats
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5399349A (en) 1992-02-06 1995-03-21 Paunescu; Calin Treatment of acne
JPH05304986A (ja) 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
US5814603A (en) * 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
GB9213215D0 (en) 1992-06-20 1992-08-05 Wellcome Found Peptides
US5349056A (en) 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
WO1994009138A1 (en) 1992-10-20 1994-04-28 Cetus Oncology Corporation Interleukin-6 receptor antagonists
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5891998A (en) 1993-06-23 1999-04-06 Istituto Di Ricerche Di Biologica Molecolare P. Angeletti S.P.A. Interleukin-6 receptor agonists
US6009875A (en) 1993-10-14 2000-01-04 Berlex Laboratories, Inc. Use of sympathetic antagonists for treatment of chronic muscle pain
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US5713367A (en) 1994-01-26 1998-02-03 Cambridge Heart, Inc. Measuring and assessing cardiac electrical stability
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5817477A (en) * 1995-06-06 1998-10-06 Human Genome Sciences, Inc. Adrenergic receptor
US5912123A (en) 1994-09-14 1999-06-15 Progenitor, Inc. Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology
US5663192A (en) 1994-10-20 1997-09-02 Eli Lilly And Company Heterocyclic neuropeptide Y receptor antagonists
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5900415A (en) 1994-11-07 1999-05-04 Pfizer Inc. Certain substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands
US5989920A (en) 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
IT1274782B (it) 1994-12-14 1997-07-24 Angeletti P Ist Richerche Bio Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130
FR2733250B1 (fr) 1995-04-21 1997-07-04 Diaclone Anticorps monoclonaux anti-gp130, et leurs utilisations
US5635503A (en) 1995-06-07 1997-06-03 Bristol-Myers Squibb Company Dihydropyridine npy antagonists: piperazine derivatives
US5674995A (en) 1995-06-07 1997-10-07 Gen-Probe Incorporated Oligonucleotides specific for cytokine signal transducer gp130 mRNA
US5668151A (en) 1995-06-07 1997-09-16 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: piperidine derivatives
US5747470A (en) 1995-06-07 1998-05-05 Gen-Probe Incorporated Method for inhibiting cellular proliferation using antisense oligonucleotides to gp130 mRNA
US5554621A (en) 1995-06-07 1996-09-10 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: nitrogen heterocyclic derivatives
US5626860A (en) 1995-06-07 1997-05-06 The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College Method for regulating metabolism with dopamine beta hydroxylase inhibitors
ZA965346B (en) 1995-06-30 1997-12-24 Lilly Co Eli Methods of treating neuropeptide Y-associated conditions.
US5972621A (en) 1995-11-27 1999-10-26 Millennium Pharmaceuticals, Inc. Methods of identifying compounds that modulate body weight using the OB receptor
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
CA2257474A1 (en) 1996-06-07 1997-12-11 Eli Lilly And Company Ob protein binding protein
US5830450A (en) 1996-06-19 1998-11-03 Lallone; Roger L. Compositions of leptin bound to an apolipoprotein
ATE230403T1 (de) 1996-07-23 2003-01-15 Neurogen Corp Einige amido- und ammo- substituierte benzylaminderivate: eine neue klasse von neuropeptid y1 spezifische ligande
WO1998003493A1 (en) 1996-07-23 1998-01-29 Neurogen Corporation Certain substituted benzylamine derivatives; a new class of neuropeptide-y1 specific ligands
US5874535A (en) 1996-08-01 1999-02-23 Incyte Pharmaceuticals, Inc. Human leptin receptor gene-related protein
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
PA8441701A1 (es) 1996-11-26 2000-05-24 Pfizer Sales dimesilato de los ligandos del neuropeptido y
US5776931A (en) 1997-01-09 1998-07-07 Eli Lilly And Company Naphthimidazolyl neuropeptide Y receptor antagonists
WO1998035957A1 (en) 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
US6001836A (en) 1997-05-28 1999-12-14 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: cyanoguanidine derivatives
US5889016A (en) 1997-06-26 1999-03-30 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists
US5985616A (en) 1998-01-07 1999-11-16 Schering Corporation Chimeric mammalian NPY Y5 receptors
US5866547A (en) 1998-01-20 1999-02-02 Beth Israel Deaconess Medical Center Methods of neuroendocrine regulation of affective disorders
EP0950417A3 (de) * 1998-02-23 2000-02-23 Pfizer Products Inc. Behandlung von Skeletterkrankungen
US6214812B1 (en) * 1998-04-02 2001-04-10 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US6303573B1 (en) 1999-06-07 2001-10-16 The Burnham Institute Heart homing peptides and methods of using same
AUPQ199999A0 (en) * 1999-08-03 1999-08-26 University Of Melbourne, The A method of treatment and agents useful for same
US6313172B1 (en) 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity

Also Published As

Publication number Publication date
EP1542719A2 (de) 2005-06-22
WO2003049673A2 (en) 2003-06-19
JP2005516001A (ja) 2005-06-02
CN1630514A (zh) 2005-06-22
EP1542719A4 (de) 2006-06-21
CA2469306A1 (en) 2003-06-19
US20060165683A1 (en) 2006-07-27
WO2003049673A3 (en) 2005-04-21
EP2002827A2 (de) 2008-12-17
AU2002348131A1 (en) 2003-06-23

Similar Documents

Publication Publication Date Title
AU2002258592A1 (en) Compositions and methods for modulating bone mineral deposition
IL142118A0 (en) Method and composition for treatment of skeletal dysplasias
AU2002364364A8 (en) Method of treating apoptosis and compositions thereof
IL158251A0 (en) Treatment of collagen
GB2393202B (en) Methods of well treatment
ZA200410011B (en) Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
GB0228326D0 (en) Method of controlling unwanted vegitation
AU2002364125A8 (en) Antisense modulation of mdm2 expression
IL160305A0 (en) Compositions and methods for modulation of darpp-32 phosphorylation
AU2001291019A1 (en) Method of modulating neovascularization
HUP0401451A3 (en) Method for preparation of escitalopram
EP1181306A4 (de) Verbindungen und methoden zur regulierung von apoptose und methoden zur herstellung und zum screening von entsprechenden verbindungen
HUP0402252A3 (en) Method for preparation of escitalopram
AUPR255401A0 (en) Regulation of lipids and/or bone density and compositions therefor
IL162269A0 (en) Methods and compositions for control of bone formation via modulation of sympathetic tone
NO20023837D0 (no) Modulering av bendannelse
GB2377095B (en) Method of generating offset drive control signals
AU2002353078A8 (en) Tissue graft compositions and methods for producing same
EP1377156A4 (de) Verfahren zur förderung von entomophilen
HUP0402267A3 (en) Method for treatment of bone disorders
AU2002235202A1 (en) Treatment of bone disorders by modulation of fgfr3
IL160138A0 (en) Compositions and methods for modulation of viral maturation
EP1450849A4 (de) Verfahren zur behandlung von endometreose
AU2003214601A1 (en) Compositions and methods for inducing and regulating bone formation
AU2001232900A1 (en) Methods and compositions for control of bone formation via modulation of neuropeptide y activity